---
title: "One of the actual controllers of YONGAN PHARMACEUTICAL, Huanggang Yongan, intends to reduce its holdings by no more than 0.91% of the shares"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/249944892.md"
description: "According to the Zhitong Finance APP, YONGAN PHARMACEUTICAL announced that its controlling shareholder and actual controller, the concerted actor Huanggang Yongan Pharmaceutical Co., Ltd. (hereinafter referred to as \"Huanggang Yongan\"), plans to reduce its holdings of the company's shares by no more than 2.6323 million shares (accounting for 0.91% of the total share capital after excluding shares in the company's repurchase special account) through centralized bidding or block trading within three months after fifteen trading days from the date of this announcement"
datetime: "2025-07-24T11:17:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/249944892.md)
  - [en](https://longbridge.com/en/news/249944892.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/249944892.md)
---

# One of the actual controllers of YONGAN PHARMACEUTICAL, Huanggang Yongan, intends to reduce its holdings by no more than 0.91% of the shares

According to the Zhitong Finance APP, YONGAN PHARMACEUTICAL (002365.SZ) announced that its controlling shareholder and actual controller, Huanggang Yongan Pharmaceutical Co., Ltd. (hereinafter referred to as "Huanggang Yongan"), plans to reduce its holdings of the company's shares by no more than 2.6323 million shares (accounting for 0.91% of the total share capital after excluding shares in the company's repurchase special account) through centralized bidding or block trading within three months after fifteen trading days from the date of this announcement

### Related Stocks

- [002365.CN](https://longbridge.com/en/quote/002365.CN.md)

## Related News & Research

- [XCMG's Electric Mining Push Featured in The Australian Financial Review](https://longbridge.com/en/news/295381066.md)
- [FDA Issues Warning About Certain Products Containing Toxic Yellow Oleander](https://longbridge.com/en/news/295690341.md)
- [SHUKRAPHAR: Strong revenue and profit growth in Q1 FY27, with robust performance in the pharmaceutical segment](https://longbridge.com/en/news/295639972.md)
- [Revive says DRDC study finds bucillamine preserves GABA receptor signaling in nerve-agent animal model](https://longbridge.com/en/news/295660641.md)
- [CTT Pharmaceutical explores contract manufacturing partnership, talks ongoing](https://longbridge.com/en/news/295684783.md)